Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom. // Hepatobiliary & Pancreatic Diseases International. – URL: https://www.sciencedirect.com/science/article/pii/S1499387226001177?dgcid=rss_sd_all
Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom. Hepatobiliary & Pancreatic Diseases International. https://www.sciencedirect.com/science/article/pii/S1499387226001177?dgcid=rss_sd_all
“Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom.” Hepatobiliary & Pancreatic Diseases International.
@article{article100266,
title = {Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom},
journal = {Hepatobiliary \& Pancreatic Diseases International},
url = {https://www.sciencedirect.com/science/article/pii/S1499387226001177?dgcid=rss_sd_all}
}